On Wednesday, TRANSFORM LOGIC CORP (OTCMKTS:TLOG)’s shares declined -36.51% to $2.40.
TRANSFORM LOGIC CORP (TLOG) declared termination of the underwriting agreement for and cancellation of its formerly declared underwritten public offering of 6.25 million shares of the Company’s common stock at a price to the public of $4.00 per share.
William Blair & Company, L.L.C. and Nomura Securities International, Inc. were joint book-running managers for the cancelled offering. WBB Securities was serving as the co-manager for the offering.
This offering was being conducted following a shelf registration statement that was declared effective by the U.S. Securities and Exchange Commission (“SEC”) on January 15, 2015.
TetraLogic Pharmaceuticals Corporation, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics in oncology and infectious diseases. Its clinical-stage product candidate, Birinapant, is in Phase II clinical trial administered with azacitidine for the treatment of myelodysplastic syndromes.
CoLucid Pharmaceuticals Inc (NASDAQ:CLCD)’s shares dropped -20.00% to $8.00.
CoLucid Pharmaceuticals Inc (CLCD) declared the pricing of its initial public offering of 5,500,000 shares of common stock at a public offering price of $10.00 per share.
In addition, CoLucid has granted the underwriters a 30-day option to purchase up to an additional 825,000 shares of common stock at the public offering price to cover over-allotments, if any. All shares of the common stock in this offering are being sold by CoLucid. CoLucid’s shares are predictable to start trading on The NASDAQ Global Market on May 6, 2015 under the ticker symbol “CLCD.” This offering is predictable to close on May 11, 2015, subject to customary closing conditions.
CoLucid Pharmaceuticals, Inc., a biopharmaceutical company, develops small molecule for the acute treatment of migraine headaches. Its lead product candidate is Lasmiditan, an oral tablet that is in a Phase III clinical program for the acute treatment of migraine headaches in adults.
At the end of Wednesday’s trade, Crestwood Equity Partners LP (NYSE:CEQP)‘s shares dipped -16.20% to $5.60.
Crestwood Equity Partners LP (CEQP) stated its financial results for the three months ended March 31, 2015. Crestwood Equity owns the general partner of Crestwood Midstream Partners LP (CMLP) (“Crestwood Midstream” or “CMLP”).
In a separate press release issued recently, Crestwood Equity and Crestwood Midstream declared the execution of a definitive agreement to merge the two partnerships and simplify Crestwood’s corporate structure into a single publicly-traded partnership with a merged enterprise value of about $7.5 billion. Under the terms of the agreement, each common unitholder of Crestwood Midstream will receive 2.75 common units of Crestwood Equity upon closing of the transaction. Completion of the transaction is subject to the approval of Crestwood Midstream’s unitholders and customary closing conditions. The transaction is predictable to close in the third quarter 2015.
Crestwood Equity Partners LP provides midstream solutions to customers in the crude oil, natural gas liquids (NGLs), and natural gas sectors of the energy industry in the United States.
Noodles & Co (NASDAQ:NDLS), ended its Wednesday’s trading session with -19.36% loss, and closed at $16.70.
Noodles & Co (NDLS) declared financial results for its first quarter ended March 31, 2015.
Key highlights for the first quarter of 2015 as compared to the same quarter a year ago comprise:
- Total revenue raised 18.1% to $105.8 million from $89.5 million.
- Comparable restaurant sales raised 0.8% for company-owned restaurants, 1.4% for franchise restaurants and 0.9% system-wide.
- Restaurant contribution margin reduced to 16.2% from 17.3%.
- 16 new restaurants opened system-wide in the first quarter, counting 13 company-owned and three franchise restaurants.
Noodles & Company develops and operates fast casual restaurants in the United States. It offers cooked-to-order dishes, counting noodles and pasta, soups, salads, sandwiches, and appetizers.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
